↓ Skip to main content

Gene therapy for sickle cell disease

Overview of attention for article published in Cochrane database of systematic reviews, November 2016

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

wikipedia
1 Wikipedia page

Readers on

mendeley
44 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Gene therapy for sickle cell disease
Published in
Cochrane database of systematic reviews, November 2016
DOI 10.1002/14651858.cd007652.pub5
Pubmed ID
Authors
Abstract

Sickle cell disease encompasses a group of genetic disorders characterized by the presence of at least one hemoglobin S (Hb S) allele, and a second abnormal allele that could allow abnormal hemoglobin polymerisation leading to a symptomatic disorder.Autosomal recessive disorders (such as sickle cell disease) are good candidates for gene therapy because a normal phenotype can be restored in diseased cells with only a single normal copy of the mutant gene. This is an update of a previously published Cochrane Review. The objectives of this review are:to determine whether gene therapy can improve survival and prevent symptoms and complications associated with sickle cell disease;to examine the risks of gene therapy against the potential long-term gain for people with sickle cell disease. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register, which comprises of references identified from comprehensive electronic database searches and searching relevant journals and abstract books of conference proceedings.Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 15 August 2016. All randomised or quasi-randomised clinical trials (including any relevant phase 1, 2 or 3 trials) of gene therapy for all individuals with sickle cell disease, regardless of age or setting. No trials of gene therapy for sickle cell disease were found. No trials of gene therapy for sickle cell disease were reported. No randomised or quasi-randomised clinical trials of gene therapy for sickle cell disease were reported. Thus, no objective conclusions or recommendations in practice can be made on gene therapy for sickle cell disease. This systematic review has identified the need for well-designed, randomised controlled trials to assess the benefits and risks of gene therapy for sickle cell disease.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 44 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Bachelor 8 18%
Student > Master 7 16%
Student > Ph. D. Student 4 9%
Other 3 7%
Lecturer 2 5%
Other 6 14%
Unknown 14 32%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 14 32%
Biochemistry, Genetics and Molecular Biology 6 14%
Psychology 2 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Business, Management and Accounting 1 2%
Other 4 9%
Unknown 16 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 April 2018.
All research outputs
#12,543,550
of 34,826,706 outputs
Outputs from Cochrane database of systematic reviews
#11,635
of 14,800 outputs
Outputs of similar age
#132,444
of 335,221 outputs
Outputs of similar age from Cochrane database of systematic reviews
#212
of 260 outputs
Altmetric has tracked 34,826,706 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 14,800 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.7. This one is in the 14th percentile – i.e., 14% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 335,221 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 260 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.